Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

Multiple Sclerosis Journal

Volumn 17, Issue 9, 2011, Pages 1074-1078

  Sørensen, Per Soelberg ^a   Hyldgaard Jensen, Poul Erik ^a   Haghikia, Aiden ^b   Lundkvist, Malin ^c   Vedeler, Christian ^d   Sellebjerg, Finn ^a   Koch Henriksen, Nils ^a   Fogdell Hahn, Anna ^c   Myhr, Kjell Morten ^d   Hillert, Jan ^c   Gold, Ralf ^b  

^a University of Copenhagen   (Denmark)

^b ST JOSEF HOSPITAL   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

antibodies; disease modifying therapies; immunology; multiple sclerosis; Tysabri

Indexed keywords

ANTIBODY; NATALIZUMAB;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; THERAPY EFFECT;

EID: 84860396489     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511404271     Document Type: Article

References (14)

1. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23 (Pubitemid 36026342)
2. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004 ; 62: 2038-2043 (Pubitemid 38738218)
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
4. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
5. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009 ; 16: 420-423
6. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol. 2009 ;: 424-426
7. Putzki N, Yaldizli O, Maurer M, Cursiefen S, Kuckert S, Klawe C, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2009 ; 17: 31-37
8. Piehl F, Holmen C, Hillert J, Olsson T. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. 2011 ; 31 (Suppl. 3). S289 - S293
9. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004 ; 4: 571-580 (Pubitemid 38890585)
10. Stuve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007 ; 13: 79-95 (Pubitemid 46697841)
11. Sorensen PS, Tscherning T, Mathiesen HK, Langkilde AR, Ross C, Ravnborg M, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology. 2006 ; 67: 1681-1683 (Pubitemid 44747946)
12. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403 (Pubitemid 47511460)
13. Lundkvist M, Hillert J, Fogdell-Hahn A. No increased risk for antibody formation against natalizumab in multiple sclerosis patients positive for neutralising antibodies to interferon-beta. Mult Scler. 2010 ; 16 (Suppl. 10). S296 - S296
14. Sorensen PS, Koch-Henriksen N, Jensen X. PEH. Neutralizing antibodies against interferon-beta do not predispose antibodies against natalizumab. Neurology. 2011 ; 76: 759-760